Richard E Pratley

List of Publications by Year
in descending order

245 papers	25,280 citations	16791 66 h-index	8878 150 g-index
259 all docs	259 docs citations	259 times ranked	25338 citing authors

#	Article	IF	Citations
1	More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes. Pediatric Research, 2023, 93, 708-714.	1.1	2
2	Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 230-240.	1.8	24
3	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	1.6	59
4	Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Research and Care, 2022, 10, e002207.	1.2	5
5	Indirect treatment comparisons: Choosing the right tool for the job. Diabetes, Obesity and Metabolism, 2022, 24, 1180-1181.	2.2	0
6	Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 424-434.	2.4	27
7	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1114-1122.	2.2	5
8	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucoseâ€lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, , .	2.2	5
9	Can technology improve the management of older adults with type 1 diabetes? Yes, butâ€¦. The Lancet Healthy Longevity, 2022, 3, e120-e121.	2.0	2
10	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia, 2022, 65, 908-911.	2.9	0
11	An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1461-1469.	1.8	9
12	Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 diabetes. Contemporary Clinical Trials, 2022, 117, 106765.	0.8	9
13	Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. Kidney International Reports, 2022, 7, 1782-1792.	0.4	4
14	The Ile191Val Variant of the TAS1R2 Subunit of Sweet Taste Receptors Is Associated With Reduced HbA1c in a Human Cohort With Variable Levels of Glucose Homeostasis. Frontiers in Nutrition, 2022, 9, .	1.6	2
15	Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology. International Journal of Molecular Sciences, 2022, 23, 5779.	1.8	16
16	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 979-994.	2.6	13
17	Design and baseline characteristics of the <scp>AMPLITUDEâ€O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€1 receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	2.2	12
18	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 148.	3.0	625

#	Article	IF	Citations
19	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. Circulation, 2021, 143, 602-605.	1.6	24
20	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidaseâ€4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 569-580.	2.2	18
21	A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function. Circulation, 2021, 143, 145-159.	1.6	81
22	Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. Journal of Diabetes Science and Technology, 2021, 15, 582-592.	1.3	22
23	High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice. Microbiome, 2021, 9, 11.	4.9	43
24	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	4.3	30
25	Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2767-2778.	1.8	20
26	ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS ONE, 2021, 16, e0249038.	1.1	97
27	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia, 2021, 64, 1256-1267.	2.9	103
28	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Therapy, 2021, 12, 1099-1116.	1.2	8
29	Anti-interleukin-21 antibody and liraglutide for the preservation of Î²-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 212-224.	5.5	85
30	Prototype of an evidenceâ€based tool to aid individualized treatment for type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1666-1671.	2.2	4
31	Kidney outcomes using a sustained â‰¥40% decline in <scp>eGFR</scp>: A metaâ€analysis of <scp>SGLT2</scp> inhibitor trials. Clinical Cardiology, 2021, 44, 1139-1143.	0.7	20
32	Ertugliflozin and Slope of Chronic eGFR. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1345-1354.	2.2	26
33	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2058-2066.	2.2	33
34	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. Current Cardiology Reports, 2021, 23, 75.	1.3	6
35	Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry. Journal of Diabetes and Its Complications, 2021, 35, 107884.	1.2	2
36	Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1201-1209.	2.2	9

#	Article	IF	Citations
37	Twenty-four hour assessments of substrate oxidation reveal differences in metabolic flexibility in type 2 diabetes that are improved with aerobic training. Diabetologia, 2021, 64, 2322-2333.	2.9	8
38	Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes Spectrum, 2021, 34, 217-224.	0.4	0
39	An indirect treatment comparison of the efficacy of semaglutide 1.0Âmg versus dulaglutide 3.0 and 4.5Âmg. Diabetes, Obesity and Metabolism, 2021, 23, 2513-2520.	2.2	14
40	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 896-907.	13.9	339
41	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	5.5	437
42	The Ile191Val is a partial loss-of-function variant of the TAS1R2 sweet-taste receptor and is associated with reduced glucose excursions in humans. Molecular Metabolism, 2021, 54, 101339.	3.0	10
43	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Research and Care, 2021, 9, e002484.	1.2	14
44	Body Weight Loss With Oral Semaglutide is Independent of Gastrointestinal Adverse Events. Canadian Journal of Diabetes, 2021, 45, S14-S15.	0.4	0
45	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ Open Diabetes Research and Care, 2021, 9, e002339.	1.2	12
46	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Therapy, 2020, 11, 53-70.	1.2	18
47	Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptideâ€“Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. Diabetes, 2020, 69, 146-157.	0.3	11
48	Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. Diabetes Care, 2020, 43, 418-425.	4.3	23
49	Development of a hypoglycaemia risk score to identify highâ€risk individuals with advanced type 2 diabetes in DEVOTE. Diabetes, Obesity and Metabolism, 2020, 22, 2248-2256.	2.2	8
50	Dietary intake on days with and without hypoglycemia in youth with type 1 diabetes: The Flexible Lifestyle Empowering Change trial. Pediatric Diabetes, 2020, 21, 1475-1484.	1.2	4
51	Efficacy of Ertugliflozin on Heart Failureâ€“Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation, 2020, 142, 2205-2215.	1.6	156
52	Letâ€™s Be More Sensitiveâ€”How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect Î²-Cell Function in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4975-e4976.	1.8	1
53	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open, 2020, 10, e037883.	0.8	6
54	Effects of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 2487-2492.	2.2	31

#	Article	IF	Citations
55	Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. Diabetes, Obesity and Metabolism, 2020, 22, 2276-2286.	2.2	12
56	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 1425-1435.	13.9	927
57	Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes and Endocrinology,the, 2020, 8, 855-867.	5.5	47
58	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). Diabetes and Vascular Disease Research, 2020, 17, 147916412097093.	0.9	6
59	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
60	The effect of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 1690-1695.	2.2	19
61	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 2397.	3.8	191
62	An improvement in skeletal muscle mitochondrial capacity with shortâ€term aerobic training is associated with changes in Tribbles 1 expression. Physiological Reports, 2020, 8, e14416.	0.7	7
63	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	1.2	53
64	Pharmacological therapies to address obesity in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 194-206.	1.2	7
65	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 clinical trials. Diabetes, Obesity and Metabolism, 2020, 22, 2193-2198.	2.2	11
66	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trial. Diabetes, Obesity and Metabolism, 2020, 22, 2077-2088.	2.2	10
67	Evaluating glucoseâ€lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. Diabetes, Obesity and Metabolism, 2020, 22, 1231-1242.	2.2	13
68	Reproducibility of a prediabetes classification in a contemporary population. Metabolism Open, 2020, 6, 100031.	1.4	6
69	Risk of severe hypoglycaemia and its impact in type 2 diabetes in <scp>DEVOTE</scp>. Diabetes, Obesity and Metabolism, 2020, 22, 2241-2247.	2.2	11
70	Efficacy, safety and cardiovascular outcomes of onceâ€daily oral semaglutide in patients with type 2 diabetes: The <scp>PIONEER</scp> programme. Diabetes, Obesity and Metabolism, 2020, 22, 1263-1277.	2.2	68
71	The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care, 2020, 43, 806-812.	4.3	44
72	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Frontiers in Endocrinology, 2020, 11, 178.	1.5	137

#	Article	IF	Citations
73	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the <scp>DEVOTE</scp>, <scp>LEADER</scp> and <scp>SUSTAIN</scp>â€6 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2020, 22, 1537-1547.	2.2	54
74	High residual C-peptide likely contributes to glycemic control in type 1 diabetes. Journal of Clinical Investigation, 2020, 130, 1850-1862.	3.9	73
75	Longâ€term efficacy and safety of combined insulin and glucagonâ€like peptideâ€1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
76	Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes, Obesity and Metabolism, 2019, 21, 2429-2439.	2.2	25
77	Endurance training remodels skeletal muscle phospholipid composition and increases intrinsic mitochondrial respiration in men with Type 2 diabetes. Physiological Genomics, 2019, 51, 586-595.	1.0	20
78	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovascular Diabetology, 2019, 18, 156.	2.7	17
79	88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6. Canadian Journal of Diabetes, 2019, 43, S32-S33.	0.4	0
80	94 - Oral Semaglutide vs Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5. Canadian Journal of Diabetes, 2019, 43, S35-S36.	0.4	0
81	The interplay of type 1 diabetes and weight management: A qualitative study exploring thematic progression from adolescence to young adulthood. Pediatric Diabetes, 2019, 20, 974-985.	1.2	12
82	Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 520-530.	13.9	423
83	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet, The, 2019, 394, 39-50.	6.3	315
84	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 515-527.	5.5	180
85	Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data. Pharmaceutical Medicine, 2019, 33, 209-217.	1.0	7
86	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, Obesity and Metabolism, 2019, 21, 1745-1751.	2.2	22
87	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, Obesity and Metabolism, 2019, 21, 1625-1633.	2.2	18
88	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes, Obesity and Metabolism, 2019, 21, 1437-1444.	2.2	13
89	Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. Molecular Metabolism, 2019, 20, 63-78.	3.0	40
90	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine, 2019, 170, 423.	2.0	34

#	Article	IF	Citations
91	OR22-2 Exposure to Hypoglycemia in Older Adults with Type 1 Diabetes: Baseline Characteristics Using Continuous Glucose Monitoring Data. Journal of the Endocrine Society, 2019, 3, .	0.1	4
92	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 275-286.	5.5	443
93	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1111-1120.	2.2	121
94	Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 1193-1201.	2.2	6
95	Troponin T3 associates with DNA consensus sequence that overlaps with p53 binding motifs. Experimental Gerontology, 2018, 108, 35-40.	1.2	7
96	Glycaemic outcomes of anIndividualized treatMent aPproach for oldERvulnerable patIents:Arandomized, controlled stUdy in type 2 diabetesMellitus (IMPERIUM). Diabetes, Obesity and Metabolism, 2018, 20, 148-156.	2.2	13
97	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia, 2018, 61, 58-65.	2.9	124
98	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia, 2018, 61, 48-57.	2.9	126
99	Efficacy of Semaglutide vs. Dulaglutide Across Baseline HbA1C in SUSTAIN 7. Canadian Journal of Diabetes, 2018, 42, S44.	0.4	0
100	Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. Current Diabetes Reports, 2018, 18, 102.	1.7	6
101	Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocrine Reviews, 2018, 39, 629-663.	8.9	154
102	First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. Diabetes Care, 2018, 41, 2396-2403.	4.3	99
103	Rates of Major Adverse Cardiovascular Events and Mortality with Basal Insulin by Liraglutide Use: A DEVOTE Subanalysis. Canadian Journal of Diabetes, 2018, 42, S7-S8.	0.4	0
104	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
105	T1R2 receptor-mediated glucose sensing in the upper intestine potentiates glucose absorption through activation of local regulatory pathways. Molecular Metabolism, 2018, 17, 98-111.	3.0	32
106	Design and baseline characteristics of the eValuation of ERTugliflozin efflcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal, 2018, 206, 11-23.	1.2	171
107	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
108	Implications of cardiovascular outcome trials with injectable antidiabetic agents. Journal of Diabetes, 2018, 10, 801-803.	0.8	2

#	Article	IF	Citations
109	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care, 2018, 41, 1590-1599.	4.3	16
110	Exercise Response Variations in Skeletal Muscle PCr Recovery Rate and Insulin Sensitivity Relate to Muscle Epigenomic Profiles in Individuals With Type 2 Diabetes. Diabetes Care, 2018, 41, 2245-2254.	4.3	41
111	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care, 2018, 41, 2229-2235.	4.3	74
112	Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors. BMC Cancer, 2018, 18, 351.	1.1	13
113	Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2018, 12, 1184-1191.	1.3	8
114	Pioglitazone Alters the Cargo Composition of Circulating Exosomes in Subjects with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	2
115	Inhibition of sweet chemosensory receptors alters insulin responses during glucose ingestion in healthy adults: a randomized crossover interventional study. American Journal of Clinical Nutrition, 2017, 105, 1001-1009.	2.2	21
116	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	13.9	480
117	Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684â€“1692. Diabetes Care, 2017, 40, e47-e48.	4.3	1
118	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clinical Diabetes, 2017, 35, 141-153.	1.2	1
119	Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control. Journal of Nutritional Biochemistry, 2017, 49, 117-122.	1.9	25
120	Measurement of altered APP isoform expression in adipose tissue of diet-induced obese mice by absolute quantitative real-time PCR. Animal Cells and Systems, 2017, 21, 100-107.	0.8	4
121	Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps. Current Diabetes Reports, 2017, 17, 58.	1.7	46
122	Postgastric bypass hypoglycaemia in a patient with end-stage renal disease: a diagnostic and management pitfall. BMJ Case Reports, 2017, 2017, bcr-2017-220600.	0.2	0
123	Comparison Of The Long-Term Effects Of Liraglutide And Glimepiride Monotherapy On Bone Mineral Density In Patients With Type 2 Diabetes. Endocrine Practice, 2016, 22, 406-411.	1.1	48
124	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Journal, 2016, 179, 175-183.	1.2	58
125	LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. Journal of Diabetes and Its Complications, 2016, 30, 1631-1639.	1.2	5
126	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care, 2016, 39, 1684-1692.	4.3	60

#	Article	IF	Citations
127	Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity, 2016, 24, 820-828.	1.5	65
128	Effects of glucose and insulin on secretion of amyloidâ€Î²2 by human adipose tissue cells. Obesity, 2016, 24, 1471-1479.	1.5	18
129	Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. Diabetes Technology and Therapeutics, 2016, 18, 671-673.	2.4	1
130	Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. Scientific Reports, 2016, 6, 31479.	1.6	134
131	Disruption of the sugar-sensing receptor T1R2 attenuates metabolic derangements associated with diet-induced obesity. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E688-E698.	1.8	30
132	Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox. Mayo Clinic Proceedings, 2016, 91, 858-866.	1.4	24
133	Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. European Journal of Preventive Cardiology, 2016, 23, 50-58.	0.8	5
134	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care, 2016, 39, 603-610.	4.3	126
135	Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte production of proinflammatory cytokines and muscle expression of redox-sensitive genes. Journal of Nutritional Biochemistry, 2015, 26, 1599-1606.	1.9	32
136	Linagliptin use in older individuals with type 2 diabetes. Clinical Interventions in Aging, 2014, 9, 1109.	1.3	7
137	HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia, 2014, 57, 2475-2484.	2.9	111
138	Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drugâ€naÃ¯ve patients with type 2 diabetes: a randomized, doubleâ€blind, 6â€month study. Diabetes, Obesity and Metabolism, 2014, 16, 613-621.	2.2	49
139	Altered gene expression of amyloid precursor protein in the adipose tissue and brain of obese mice fed with long-term high-fat diet and streptozotocin-induced diabetic mice. Animal Cells and Systems, 2014, 18, 219-227.	0.8	4
140	Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 289-297.	5.5	293
141	Sweet Taste Receptors Regulate Basal Insulin Secretion and Contribute to Compensatory Insulin Hypersecretion During the Development of Diabetes in Male Mice. Endocrinology, 2014, 155, 2112-2121.	1.4	52
142	The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare?. Diabetologia, 2014, 57, 1273-1275.	2.9	14
143	Improved glucose tolerance with restored expression of glucose transporter 4 in C57BL/6 mice after a long period of high-fat diet feeding. Animal Cells and Systems, 2014, 18, 197-203.	0.8	5
144	Treatment of Type 2 Diabetes Mellitus in the Older Adult: A Review. Endocrine Practice, 2014, 20, 722-736.	1.1	7

#	Article	IF	Citations
145	The Early Treatment of Type 2 Diabetes. American Journal of Medicine, 2013, 126, S2-S9.	0.6	49
146	Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylureaâ€•metformin therapy: a randomized, doubleâ€blind study (Tâ€•emerge 6). Diabetes, Obesity and Metabolism, 2013, 15, 234-240.	2.2	18
147	Liraglutide Achieves A1C Targets More often than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C <8.0%. Endocrine Practice, 2013, 19, 64-72.	1.1	15
148	Obesity and Asthma. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 598-605.	2.5	273
149	Clinical Management of Elderly Patients with Type 2 Diabetes Mellitus. Postgraduate Medicine, 2012, 124, 133-143.	0.9	28
150	Diabetes in Older Adults. Diabetes Care, 2012, 35, 2650-2664.	4.3	961
151	Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 1986-1993.	4.3	58
152	Diabetes in Older Adults: A Consensus Report. Journal of the American Geriatrics Society, 2012, 60, 2342-2356.	1.3	417
153	Associations of Fatty Acids in Cerebrospinal Fluid with Peripheral Glucose Concentrations and Energy Metabolism. PLoS ONE, 2012, 7, e41503.	1.1	26
154	Measurement of Altered AÎ²PP Isoform Expression in Frontal Cortex of Patients with Alzheimer's Disease by Absolute Quantification Real-Time PCR. Journal of Alzheimer's Disease, 2012, 29, 449-457.	1.2	13
155	Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation, 2011, 124, 695-703.	1.6	69
156	Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes â‰¥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies. American Journal of Geriatric Pharmacotherapy, 2011, 9, 423-433.	3.0	51
157	Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. Endocrine Practice, 2011, 17, 906-913.	1.1	44
158	Does the Metabolic Syndrome Carry Additional Risk for Myocardial Infarction?. Current Diabetes Reports, 2011, 11, 149-150.	1.7	0
159	Alternative and Complementary Treatments for Metabolic Syndrome. Current Diabetes Reports, 2011, 11, 173-178.	1.7	14
160	Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. Current Diabetes Reports, 2011, 11, 179-184.	1.7	98
161	Central and Peripheral Endocannabinoids and Cognate Acylethanolamides in Humans: Association with Race, Adiposity, and Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 787-791.	1.8	46
162	Beta-Cell Preservationâ€¦Is Weight Loss the Answer?. Review of Diabetic Studies, 2011, 8, 446-453.	0.5	4

#	Article	IF	Citations
163	Focus on Incretin-Based Therapies for Elderly Patients with Type 2 Diabetes. Endocrine Practice, 2011, 17, 20-26.	1.1	0
164	Ezetimibe/Simvastatin or Atorvastatin for the Treatment of Hypercholesterolemia in Patients with the Metabolic Syndrome: The VYMET Study. Current Diabetes Reports, 2010, 10, 173-175.	1.7	5
165	Advances in the treatment of prediabetes. Therapeutic Advances in Endocrinology and Metabolism, 2010, 1, 5-14.	1.4	18
166	GIP: An Inconsequential Incretin or Not?. Diabetes Care, 2010, 33, 1691-1692.	4.3	9
167	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, The, 2010, 375, 1447-1456.	6.3	534
168	Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 81-88.	1.8	83
169	Plasma Amyloid-Î² Peptide Levels Correlate with Adipocyte Amyloid Precursor Protein Gene Expression in Obese Individuals. Neuroendocrinology, 2009, 90, 383-390.	1.2	61
170	Expanding Treatment Options for Type 2 Diabetes The Old and the New. The Diabetes Educator, 2009, 35, 4S-11S.	2.6	7
171	Weight loss and diets: Which diet works best?. Current Diabetes Reports, 2009, 9, 35-36.	1.7	0
172	Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. Journal of the American Geriatrics Society, 2009, 57, 2011-2019.	1.3	71
173	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Current Medical Research and Opinion, 2009, 25, 2361-2371.	0.9	124
174	Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2009, 10, 503-512.	0.9	56
175	Dysregulation of cannabinoid CB1 receptor expression in subcutaneous adipocytes of obese individuals. Animal Cells and Systems, 2009, 13, 371-379.	0.8	5
176	LAP-BAND or medical therapy for metabolic syndrome?. Current Diabetes Reports, 2008, 8, 5-6.	1.7	0
177	Amyloid Precursor Protein Expression Is Upregulated in Adipocytes in Obesity. Obesity, 2008, 16, 1493-1500.	1.5	84
178	The cannabinoid CB1 receptor is expressed in pancreatic Î´-cells. Biochemical and Biophysical Research Communications, 2008, 372, 595-600.	1.0	38
179	Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Review of Diabetic Studies, 2008, 5, 73-94.	0.5	95
180	Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes. Current Diabetes Reviews, 2008, 4, 129-145.	0.6	25

#	Article	IF	Citations
181	Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape Journal of Medicine, 2008, 10, 171.	0.6	35
182	Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Journal of the American Academy of Nurse Practitioners, 2008, 20 Suppl 1, 7-11.	1.4	1
183	Management of Type 2 Diabetes in Treatment-Naive Elderly Patients: Benefits and risks of vildagliptin monotherapy. Diabetes Care, 2007, 30, 3017-3022.	4.3	112
184	Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 450-451.	2.9	8
185	The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?. Diabetes and Vascular Disease Research, 2007, 4, 237-240.	0.9	1
186	Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. Diabetes Care, 2007, 30, 753-759.	4.3	1,148
187	Review: Pre-diabetes: clinical relevance and therapeutic approach. British Journal of Diabetes and Vascular Disease, 2007, 7, 120-129.	0.6	18
188	On rendering continuous glucose monitoring ready for prime time in the cardiac care unit. Coronary Artery Disease, 2007, 18, 405-409.	0.3	4
189	Long-term glycemic control through preserved Î²-cell function. Current Medical Research and Opinion, 2007, 23, 904-904.	0.9	0
190	Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current Medical Research and Opinion, 2007, 23, 919-931.	0.9	166
191	The DREAM trial: Using ramipril and rosiglitazone to prevent diabetes. Current Diabetes Reports, 2007, 7, 53-55.	1.7	1
192	Metabolic syndrome: Why the controversy?. Current Diabetes Reports, 2007, 7, 56-59.	1.7	9
193	Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2006, 35, 6-11.	1.2	16
194	Insulin resistance increases PAI-1 in the heart. Biochemical and Biophysical Research Communications, 2006, 346, 102-107.	1.0	22
195	Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sciences, 2006, 79, 1600-1605.	2.0	17
196	The PROactive study: Pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes. Current Diabetes Reports, 2006, 6, 45-46.	1.7	11
197	Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Current Diabetes Reports, 2006, 6, 47-54.	1.7	70
198	Review: Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes. British Journal of Diabetes and Vascular Disease, 2006, 6, 150-156.	0.6	13

#	Article	IF	Citations
199	Rimonabant: A novel treatment for obesity and the metabolic syndrome. Current Diabetes Reports, 2005, 5, 43-44.	1.7	5
200	The evolving role of inflammation in obesity and the metabolic syndrome. Current Diabetes Reports, 2005, 5, 70-75.	1.7	308
201	Â-Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide. Diabetes Care, 2005, 28, 1132-1138.	4.3	25
202	Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight. Metabolism: Clinical and Experimental, 2004, 53, 904-911.	1.5	20
203	Taste preferences and body weight changes in an obesity-prone population. American Journal of Clinical Nutrition, 2004, 79, 372-378.	2.2	160
204	Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet, The, 2003, 361, 1861-1865.	6.3	258
205	High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes. Diabetes, 2002, 51, 455-461.	0.3	672
206	Sex differences in the human brainâ€™s response to hunger and satiation. American Journal of Clinical Nutrition, 2002, 75, 1017-1022.	2.2	120
207	Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis, 2002, 161, 233-242.	0.4	198
208	Plasma Adiponectin Concentration Is Associated With Skeletal Muscle Insulin Receptor Tyrosine Phosphorylation, and Low Plasma Concentration Precedes a Decrease in Whole-Body Insulin Sensitivity in Humans. Diabetes, 2002, 51, 1884-1888.	0.3	491
209	UCP5/BMCP1 transcript isoforms in human skeletal muscle: relationship of the short-insert isoform with lipid oxidation and resting metabolic rates. Molecular Genetics and Metabolism, 2002, 75, 369-373.	0.5	15
210	The quality of fat in the diet and its impact on insulin sensitivity. Current Diabetes Reports, 2002, 2, 69-70.	1.7	1
211	Progression from IGT to type 2 diabetes mellitus: The central role of impaired early insulin secretion. Current Diabetes Reports, 2002, 2, 242-248.	1.7	33
212	High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes. Diabetes, 2002, 51, 1889-1895.	0.3	615
213	Subcutaneous Abdominal Adipocyte Size, a Predictor of Type 2 Diabetes, Is Linked to Chromosome 1q21â€“q23 and Is Associated with a Common Polymorphism in LMNA in Pima Indians. Molecular Genetics and Metabolism, 2001, 72, 231-238.	0.5	65
214	Reduced Skeletal Muscle Calpain-10 Transcript Level Is Due to a Cumulative Decrease in Major Isoforms. Molecular Genetics and Metabolism, 2001, 73, 111-113.	0.5	35
215	Rapid Acting Insulinotropic Agents: Restoration of Early Insulin Secretion as a Physiologic Approach to Improve Glucose Control. Current Pharmaceutical Design, 2001, 7, 1375-1397.	0.9	32
216	Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Movement Disorders, 2001, 16, 924-927.	2.2	41

#	Article	IF	Citations
217	Circulating Interleukinâ€6 in Relation to Adiposity, Insulin Action, and Insulin Secretion. Obesity, 2001, 9, 414-417.	4.0	507
218	Effect of Satiation on Brain Activity in Obese and Lean Women. Obesity, 2001, 9, 676-684.	4.0	184
219	Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1930-1935.	1.8	3,039
220	A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. Journal of Clinical Investigation, 2000, 106, R69-R73.	3.9	254
221	Aerobic Exercise Trainingâ€Induced Reductions in Abdominal Fat and Glucoseâ€Stimulated Insulin Responses in Middleâ€Aged and Older Men. Journal of the American Geriatrics Society, 2000, 48, 1055-1061.	1.3	73
222	Higher sedentary energy expenditure in patients with Huntington's disease. Annals of Neurology, 2000, 47, 64-70.	2.8	138
223	Relationship Between Birth Weight and Body Composition, Energy Metabolism, and Sympathetic Nervous System Activity Later in Life. Obesity, 2000, 8, 559-565.	4.0	55
224	Type 2 Diabetes. Prediction and Prevention. G. A. Hitman, editor. Chichester: John Wiley and Sons. 1999. Â£80 ISBN 0 471 985595 3. British Journal of Nutrition, 2000, 83, 335-336.	1.2	0
225	Energy Expenditure, Fat Oxidation, and Body Weight Regulation: A Study of Metabolic Adaptation to Long- Term Weight Change. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1087-1094.	1.8	126
226	Ethnic Differences in Insulinemia and Sympathetic Tone as Links Between Obesity and Blood Pressure. Hypertension, 2000, 36, 531-537.	1.3	123
227	A shocking case of diabetic neuropathy. Lancet, The, 2000, 355, 1560.	6.3	0
228	Higher sedentary energy expenditure in patients with Huntington's disease. , 2000, 47, 64.		4
229	The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation, 1999, 104, 787-794.	3.9	1,559
230	Insulin receptor autophosphorylation in cultured myoblasts correlates to glucose disposal in Pima Indians. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E990-E994.	1.8	9
231	Regions of the human brain affected during a liquid-meal taste perception in the fasting state: a positron emission tomography study. American Journal of Clinical Nutrition, 1999, 70, 806-810.	2.2	67
232	Molecular scanning of the beta-3-adrenergic receptor gene in Pima Indians and Caucasians. Diabetes/Metabolism Research and Reviews, 1999, 15, 175-180.	1.7	3
233	Fasting and Postprandial Plasma Concentrations of Acylationâ€Stimulation Protein (ASP) in Lean and Obese Pima Indians Compared to Caucasians. Obesity, 1999, 7, 444-452.	4.0	38
234	The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older menâ˜†. American Journal of Hypertension, 1998, 11, 1405-1412.	1.0	100

#	Article	IF	Citations
235	Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. Metabolism: Clinical and Experimental, 1998, 47, 1075-1082.	1.5	86
236	Variations in the Vitamin D-Binding Protein (GcLocus) Are Associated with Oral Glucose Tolerance in Nondiabetic Pima Indians. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2993-2996.	1.8	64
237	Geneâ€"environment interactions in the pathogenesis of type 2 diabetes mellitus: lessons learned from the Pima Indians. Proceedings of the Nutrition Society, 1998, 57, 175-181.	0.4	70
238	Acute and Chronic Resistive Exercise Increase Urinary Chromium Excretion in Men as Measured with an Enriched Chromium Stable Isotope ,. Journal of Nutrition, 1998, 128, 73-78.	1.3	40
239	Relationship Between Muscle Sympathetic Nerve Activity and Plasma Leptin Concentration. Obesity, 1997, 5, 338-340.	4.0	94
240	Relatively low plasma leptin concentrations precede weight gain in Pima Indians. Nature Medicine, 1997, 3, 238-240.	15.2	238
241	Relationship of the white blood cell count to body fat: role of leptin. British Journal of Haematology, 1997, 99, 447-451.	1.2	53
242	Genomic Structure and Promoter Analysis of the Human obese Gene. Journal of Biological Chemistry, 1996, 271, 3971-3974.	1.6	186
243	Effects of weight loss on norepinephrine and insulin levels in obese older men. Metabolism: Clinical and Experimental, 1995, 44, 438-444.	1.5	19
244	Relation of the White Blood Cell Count to Obesity and Insulin Resistance: Effect of Race and Gender. Obesity, 1995, 3, 563-571.	4.0	70
245	Electrophysiologic effects of epinephrine in humans. Journal of the American College of Cardiology, 1988, 11, 1235-1244.	1.2	62